Back to top
more

STERIS (STE)

(Delayed Data from NYSE)

$225.82 USD

225.82
918,612

+0.64 (0.28%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $225.70 -0.12 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) owing to a strong recovery in base business and raised 2022 outlook.

Globus Medical (GMED) Stock Fell on Preliminary Q1 Sales Results

by Zacks Equity Research

Globus Medical's (GMED) Q1 preliminary sales results reflect an increase in procedural volumes along with growth in Enabling Technologies business.

Zacks Industry Outlook Highlights Alcon, STERIS and Abiomed

by Zacks Equity Research

Alcon, STERIS and Abiomed have been highlighted in this Industry Outlook article.

Here's Why You Should Retain Bio-Rad (BIO) Stock For Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO) owing to a recovery in most of its key global markets as well as an uptick in demand for COVID-related products.

Thermo Fisher (TMO) Debuts GMP-Manufactured Cas9 Protein

by Zacks Equity Research

Thermo Fisher's (TMO) Gibco CTS TrueCut Cas9 Protein to support genome editing for research and manufacturing applications.

Urmimala Biswas headshot

3 Medical Instruments Stocks to Buy Despite Industry Headwinds

by Urmimala Biswas

The Zacks Medical - Instruments industry is growing on R&D investments. ALC, STE and ABMD are set to gain the most. Yet, demand for non-COVID businesses is on the decline with the new COVID variant disrupting the trend.

Henry Schein (HSIC) Stock Moves Up 20.6%: What's Driving It?

by Zacks Equity Research

Henry Schein's (HSIC) stock rallied on strong fourth-quarter performance and bullish 2022 EPS guidance.

Here's Why You Should Hold on to Insulet (PODD) Stock For Now

by Zacks Equity Research

Investors are optimistic about Insulet (PODD) on robust uptake of the Omnipod system and bullish guidance.

STERIS (STE) Up 8% Since Q3 Earnings: What's Driving It?

by Zacks Equity Research

Investors are optimistic about STERIS' (STE) robust segmental growth and noteworthy acquisitions in the healthcare and pharmaceutical spaces.

STERIS (STE) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about STERIS (STE) on impressive growth across its operating segments.

Here's Why You Should Retain STERIS (STE) Stock For Now

by Zacks Equity Research

Investors are optimistic about STERIS' (STE) robust segmental performance and upbeat 2022 guidance.

Why Is Steris (STE) Down 3.7% Since Last Earnings Report?

by Zacks Equity Research

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

STERIS (STE) Strategic Buyouts Aid Growth, Margin Woe Stays

by Zacks Equity Research

STERIS' (STE) significant revenues from acquisitions of Key Surgical and Cantel Medical appear promising.

Here's Why You Should Hold on to STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) on its better-than-expected earnings in the fiscal third quarter and the ongoing integration of the Cantel Medical business.

STERIS (STE) Q3 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

STERIS (STE) reports better-than-expected earnings for the third quarter of fiscal 2022 and robust segmental growth driving the top line.

Steris (STE) Surpasses Q3 Earnings Estimates

by Zacks Equity Research

Steris (STE) delivered earnings and revenue surprises of 8.72% and 0.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Steris (STE) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

STERIS (STE) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

The ongoing integration of Cantel Medical business and robust demand from medical device customers are expected to have contributed to STERIS' (STE) Q3 performance.

Here's Why You Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS' (STE) strong segmental performance and bullish 2022 outlook.

STERIS (STE) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Strong segmental performances are driving the top line for STERIS (STE).

Steris (STE) Upgraded to Buy: Here's Why

by Zacks Equity Research

Steris (STE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

STERIS (STE) Plans Sale of Non-Core Arm for Debt Repayment

by Zacks Equity Research

The latest spin-off of STERIS' (STE) Renal Care business is expected to partly reduce the company's debt burden.

Here's Why You Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) owing to strong segmental growth and bullish 2022 outlook.

Zacks Industry Outlook Highlights: Thermo Fisher Scientific, STERIS and Accuray

by Zacks Equity Research

Zacks Industry Outlook Highlights: Thermo Fisher Scientific, STERIS and Accuray

Urmimala Biswas headshot

3 Top Medical Instruments Stocks to Counter Industry Headwinds

by Urmimala Biswas

The Zacks Medical - Instruments industry is growing on COVID-support business gains. TMO, STE and ARAY are set to gain the most. Yet, demand for base business is on the decline with the new COVID variant disrupting the trend.